Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Financial Lp Hrt Sells 9,022 Shares of Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 9,022 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $3.51, for a total value of $31,667.22. Following the transaction, the insider owned 81,385 shares in the company, valued at $285,661.35. This trade represents a 9.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, July 2nd, Financial Lp Hrt acquired 7,851 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average cost of $3.54 per share, for a total transaction of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt bought 3,959 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average price of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average cost of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt purchased 25,836 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average price of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Stock Performance

SHPH stock opened at $3.26 on Wednesday. The company has a market capitalization of $2.09 million, a PE ratio of -0.07 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a one year low of $2.90 and a one year high of $55.90. The company’s 50 day moving average price is $5.43 and its two-hundred day moving average price is $10.37.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday. Weiss Ratings raised Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals in the 4th quarter worth $26,000. Boothbay Fund Management LLC bought a new position in shares of Shuttle Pharmaceuticals during the fourth quarter valued at about $37,000. Ikarian Capital LLC purchased a new stake in shares of Shuttle Pharmaceuticals during the fourth quarter worth about $124,000. Finally, Connective Capital Management LLC bought a new stake in shares of Shuttle Pharmaceuticals in the third quarter worth about $357,000. 4.58% of the stock is currently owned by institutional investors.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .